img

Global Recombinant Antihemophilic Factor Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Recombinant Antihemophilic Factor Market Insights, Forecast to 2034

Recombinant antihemophilic factor works by temporarily raising levels of factor VIII in the blood to aid in clotting.
Global Recombinant Antihemophilic Factor market is expected to reach to US$ 2260 million in 2024, with a positive growth of %, compared with US$ 2152 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Recombinant Antihemophilic Factor industry is evaluated to reach US$ 2994.2 million in 2029. The CAGR will be 4.8% during 2024 to 2029.
The market for recombinant antihemophilic factor has witnessed significant growth in recent years. This can be attributed to several factors, including the increasing prevalence of hemophilia, advancements in recombinant DNA technology, and improved access to healthcare services. Hemophilia is a genetic bleeding disorder that requires lifelong treatment with antihemophilic factors, such as factor VIII or factor IX. Recombinant antihemophilic factor, produced using recombinant DNA technology, offers advantages over plasma-derived products, including enhanced safety, reduced risk of infection transmission, and increased supply stability.
Report Covers
This report presents an overview of global Recombinant Antihemophilic Factor market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Recombinant Antihemophilic Factor market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Takeda
Bayer
CSL
Pfizer
Biogen
Octapharma
Novo Nordisk
Sanofi
Sobi
Segment by Type
200IU
250IU

Segment by Application


Hospital
Pharmacy

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Recombinant Antihemophilic Factor plant distribution, commercial date of Recombinant Antihemophilic Factor, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Recombinant Antihemophilic Factor introduction, etc. Recombinant Antihemophilic Factor Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Recombinant Antihemophilic Factor
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Recombinant Antihemophilic Factor Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant Antihemophilic Factor Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 200IU
1.2.3 250IU
1.3 Market by Application
1.3.1 Global Recombinant Antihemophilic Factor Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Recombinant Antihemophilic Factor Sales Estimates and Forecasts 2018-2029
2.2 Global Recombinant Antihemophilic Factor Revenue by Region
2.2.1 Global Recombinant Antihemophilic Factor Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Recombinant Antihemophilic Factor Revenue by Region (2018-2024)
2.2.3 Global Recombinant Antihemophilic Factor Revenue by Region (2024-2029)
2.2.4 Global Recombinant Antihemophilic Factor Revenue Market Share by Region (2018-2029)
2.3 Global Recombinant Antihemophilic Factor Sales Estimates and Forecasts 2018-2029
2.4 Global Recombinant Antihemophilic Factor Sales by Region
2.4.1 Global Recombinant Antihemophilic Factor Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Recombinant Antihemophilic Factor Sales by Region (2018-2024)
2.4.3 Global Recombinant Antihemophilic Factor Sales by Region (2024-2029)
2.4.4 Global Recombinant Antihemophilic Factor Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Recombinant Antihemophilic Factor Sales by Manufacturers
3.1.1 Global Recombinant Antihemophilic Factor Sales by Manufacturers (2018-2024)
3.1.2 Global Recombinant Antihemophilic Factor Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Antihemophilic Factor in 2022
3.2 Global Recombinant Antihemophilic Factor Revenue by Manufacturers
3.2.1 Global Recombinant Antihemophilic Factor Revenue by Manufacturers (2018-2024)
3.2.2 Global Recombinant Antihemophilic Factor Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Antihemophilic Factor Revenue in 2022
3.3 Global Key Players of Recombinant Antihemophilic Factor, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Recombinant Antihemophilic Factor Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Recombinant Antihemophilic Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Recombinant Antihemophilic Factor, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Recombinant Antihemophilic Factor, Product Offered and Application
3.8 Global Key Manufacturers of Recombinant Antihemophilic Factor, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Recombinant Antihemophilic Factor Sales by Type
4.1.1 Global Recombinant Antihemophilic Factor Historical Sales by Type (2018-2024)
4.1.2 Global Recombinant Antihemophilic Factor Forecasted Sales by Type (2024-2029)
4.1.3 Global Recombinant Antihemophilic Factor Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Antihemophilic Factor Revenue by Type
4.2.1 Global Recombinant Antihemophilic Factor Historical Revenue by Type (2018-2024)
4.2.2 Global Recombinant Antihemophilic Factor Forecasted Revenue by Type (2024-2029)
4.2.3 Global Recombinant Antihemophilic Factor Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Antihemophilic Factor Price by Type
4.3.1 Global Recombinant Antihemophilic Factor Price by Type (2018-2024)
4.3.2 Global Recombinant Antihemophilic Factor Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Recombinant Antihemophilic Factor Sales by Application
5.1.1 Global Recombinant Antihemophilic Factor Historical Sales by Application (2018-2024)
5.1.2 Global Recombinant Antihemophilic Factor Forecasted Sales by Application (2024-2029)
5.1.3 Global Recombinant Antihemophilic Factor Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Antihemophilic Factor Revenue by Application
5.2.1 Global Recombinant Antihemophilic Factor Historical Revenue by Application (2018-2024)
5.2.2 Global Recombinant Antihemophilic Factor Forecasted Revenue by Application (2024-2029)
5.2.3 Global Recombinant Antihemophilic Factor Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Antihemophilic Factor Price by Application
5.3.1 Global Recombinant Antihemophilic Factor Price by Application (2018-2024)
5.3.2 Global Recombinant Antihemophilic Factor Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Recombinant Antihemophilic Factor Market Size by Type
6.1.1 US & Canada Recombinant Antihemophilic Factor Sales by Type (2018-2029)
6.1.2 US & Canada Recombinant Antihemophilic Factor Revenue by Type (2018-2029)
6.2 US & Canada Recombinant Antihemophilic Factor Market Size by Application
6.2.1 US & Canada Recombinant Antihemophilic Factor Sales by Application (2018-2029)
6.2.2 US & Canada Recombinant Antihemophilic Factor Revenue by Application (2018-2029)
6.3 US & Canada Recombinant Antihemophilic Factor Market Size by Country
6.3.1 US & Canada Recombinant Antihemophilic Factor Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Recombinant Antihemophilic Factor Sales by Country (2018-2029)
6.3.3 US & Canada Recombinant Antihemophilic Factor Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Recombinant Antihemophilic Factor Market Size by Type
7.1.1 Europe Recombinant Antihemophilic Factor Sales by Type (2018-2029)
7.1.2 Europe Recombinant Antihemophilic Factor Revenue by Type (2018-2029)
7.2 Europe Recombinant Antihemophilic Factor Market Size by Application
7.2.1 Europe Recombinant Antihemophilic Factor Sales by Application (2018-2029)
7.2.2 Europe Recombinant Antihemophilic Factor Revenue by Application (2018-2029)
7.3 Europe Recombinant Antihemophilic Factor Market Size by Country
7.3.1 Europe Recombinant Antihemophilic Factor Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Recombinant Antihemophilic Factor Sales by Country (2018-2029)
7.3.3 Europe Recombinant Antihemophilic Factor Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 UK
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Recombinant Antihemophilic Factor Market Size
8.1.1 China Recombinant Antihemophilic Factor Sales (2018-2029)
8.1.2 China Recombinant Antihemophilic Factor Revenue (2018-2029)
8.2 China Recombinant Antihemophilic Factor Market Size by Application
8.2.1 China Recombinant Antihemophilic Factor Sales by Application (2018-2029)
8.2.2 China Recombinant Antihemophilic Factor Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Recombinant Antihemophilic Factor Market Size by Type
9.1.1 Asia Recombinant Antihemophilic Factor Sales by Type (2018-2029)
9.1.2 Asia Recombinant Antihemophilic Factor Revenue by Type (2018-2029)
9.2 Asia Recombinant Antihemophilic Factor Market Size by Application
9.2.1 Asia Recombinant Antihemophilic Factor Sales by Application (2018-2029)
9.2.2 Asia Recombinant Antihemophilic Factor Revenue by Application (2018-2029)
9.3 Asia Recombinant Antihemophilic Factor Sales by Region
9.3.1 Asia Recombinant Antihemophilic Factor Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Recombinant Antihemophilic Factor Revenue by Region (2018-2029)
9.3.3 Asia Recombinant Antihemophilic Factor Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Market Size by Type
10.1.1 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Market Size by Application
10.2.1 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Country
10.3.1 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Takeda
11.1.1 Takeda Company Information
11.1.2 Takeda Overview
11.1.3 Takeda Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Takeda Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Takeda Recent Developments
11.2 Bayer
11.2.1 Bayer Company Information
11.2.2 Bayer Overview
11.2.3 Bayer Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Bayer Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayer Recent Developments
11.3 CSL
11.3.1 CSL Company Information
11.3.2 CSL Overview
11.3.3 CSL Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 CSL Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 CSL Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Pfizer Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Biogen
11.5.1 Biogen Company Information
11.5.2 Biogen Overview
11.5.3 Biogen Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Biogen Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Biogen Recent Developments
11.6 Octapharma
11.6.1 Octapharma Company Information
11.6.2 Octapharma Overview
11.6.3 Octapharma Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Octapharma Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Octapharma Recent Developments
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Information
11.7.2 Novo Nordisk Overview
11.7.3 Novo Nordisk Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Novo Nordisk Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Novo Nordisk Recent Developments
11.8 Sanofi
11.8.1 Sanofi Company Information
11.8.2 Sanofi Overview
11.8.3 Sanofi Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Sanofi Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Sanofi Recent Developments
11.9 Sobi
11.9.1 Sobi Company Information
11.9.2 Sobi Overview
11.9.3 Sobi Recombinant Antihemophilic Factor Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Sobi Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sobi Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Antihemophilic Factor Industry Chain Analysis
12.2 Recombinant Antihemophilic Factor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Antihemophilic Factor Production Mode & Process
12.4 Recombinant Antihemophilic Factor Sales and Marketing
12.4.1 Recombinant Antihemophilic Factor Sales Channels
12.4.2 Recombinant Antihemophilic Factor Distributors
12.5 Recombinant Antihemophilic Factor Customers
13 Market Dynamics
13.1 Recombinant Antihemophilic Factor Industry Trends
13.2 Recombinant Antihemophilic Factor Market Drivers
13.3 Recombinant Antihemophilic Factor Market Challenges
13.4 Recombinant Antihemophilic Factor Market Restraints
14 Key Findings in The Global Recombinant Antihemophilic Factor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Recombinant Antihemophilic Factor Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of 200IU
Table 3. Major Manufacturers of 250IU
Table 4. Global Recombinant Antihemophilic Factor Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Recombinant Antihemophilic Factor Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Recombinant Antihemophilic Factor Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Recombinant Antihemophilic Factor Revenue Market Share by Region (2018-2024)
Table 9. Global Recombinant Antihemophilic Factor Revenue Market Share by Region (2024-2029)
Table 10. Global Recombinant Antihemophilic Factor Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Recombinant Antihemophilic Factor Sales by Region (2018-2024) & (K Units)
Table 12. Global Recombinant Antihemophilic Factor Sales by Region (2024-2029) & (K Units)
Table 13. Global Recombinant Antihemophilic Factor Sales Market Share by Region (2018-2024)
Table 14. Global Recombinant Antihemophilic Factor Sales Market Share by Region (2024-2029)
Table 15. Global Recombinant Antihemophilic Factor Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Recombinant Antihemophilic Factor Sales Share by Manufacturers (2018-2024)
Table 17. Global Recombinant Antihemophilic Factor Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Recombinant Antihemophilic Factor Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Recombinant Antihemophilic Factor, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Recombinant Antihemophilic Factor Price by Manufacturers 2018-2024 (USD/Unit)
Table 21. Global Recombinant Antihemophilic Factor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Recombinant Antihemophilic Factor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Antihemophilic Factor as of 2022)
Table 23. Global Key Manufacturers of Recombinant Antihemophilic Factor, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Recombinant Antihemophilic Factor, Product Offered and Application
Table 25. Global Key Manufacturers of Recombinant Antihemophilic Factor, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Recombinant Antihemophilic Factor Sales by Type (2018-2024) & (K Units)
Table 28. Global Recombinant Antihemophilic Factor Sales by Type (2024-2029) & (K Units)
Table 29. Global Recombinant Antihemophilic Factor Sales Share by Type (2018-2024)
Table 30. Global Recombinant Antihemophilic Factor Sales Share by Type (2024-2029)
Table 31. Global Recombinant Antihemophilic Factor Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Recombinant Antihemophilic Factor Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Recombinant Antihemophilic Factor Revenue Share by Type (2018-2024)
Table 34. Global Recombinant Antihemophilic Factor Revenue Share by Type (2024-2029)
Table 35. Recombinant Antihemophilic Factor Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Recombinant Antihemophilic Factor Price Forecast by Type (2024-2029) & (USD/Unit)
Table 37. Global Recombinant Antihemophilic Factor Sales by Application (2018-2024) & (K Units)
Table 38. Global Recombinant Antihemophilic Factor Sales by Application (2024-2029) & (K Units)
Table 39. Global Recombinant Antihemophilic Factor Sales Share by Application (2018-2024)
Table 40. Global Recombinant Antihemophilic Factor Sales Share by Application (2024-2029)
Table 41. Global Recombinant Antihemophilic Factor Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Recombinant Antihemophilic Factor Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Recombinant Antihemophilic Factor Revenue Share by Application (2018-2024)
Table 44. Global Recombinant Antihemophilic Factor Revenue Share by Application (2024-2029)
Table 45. Recombinant Antihemophilic Factor Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Recombinant Antihemophilic Factor Price Forecast by Application (2024-2029) & (USD/Unit)
Table 47. US & Canada Recombinant Antihemophilic Factor Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Recombinant Antihemophilic Factor Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Recombinant Antihemophilic Factor Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Recombinant Antihemophilic Factor Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Recombinant Antihemophilic Factor Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Recombinant Antihemophilic Factor Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Recombinant Antihemophilic Factor Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Recombinant Antihemophilic Factor Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Recombinant Antihemophilic Factor Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Recombinant Antihemophilic Factor Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Recombinant Antihemophilic Factor Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Recombinant Antihemophilic Factor Sales by Country (2024-2029) & (K Units)
Table 60. Europe Recombinant Antihemophilic Factor Sales by Type (2018-2024) & (K Units)
Table 61. Europe Recombinant Antihemophilic Factor Sales by Type (2024-2029) & (K Units)
Table 62. Europe Recombinant Antihemophilic Factor Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Recombinant Antihemophilic Factor Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Recombinant Antihemophilic Factor Sales by Application (2018-2024) & (K Units)
Table 65. Europe Recombinant Antihemophilic Factor Sales by Application (2024-2029) & (K Units)
Table 66. Europe Recombinant Antihemophilic Factor Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Recombinant Antihemophilic Factor Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Recombinant Antihemophilic Factor Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Recombinant Antihemophilic Factor Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Recombinant Antihemophilic Factor Sales by Country (2018-2024) & (K Units)
Table 72. Europe Recombinant Antihemophilic Factor Sales by Country (2024-2029) & (K Units)
Table 73. China Recombinant Antihemophilic Factor Sales by Type (2018-2024) & (K Units)
Table 74. China Recombinant Antihemophilic Factor Sales by Type (2024-2029) & (K Units)
Table 75. China Recombinant Antihemophilic Factor Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Recombinant Antihemophilic Factor Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Recombinant Antihemophilic Factor Sales by Application (2018-2024) & (K Units)
Table 78. China Recombinant Antihemophilic Factor Sales by Application (2024-2029) & (K Units)
Table 79. China Recombinant Antihemophilic Factor Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Recombinant Antihemophilic Factor Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Recombinant Antihemophilic Factor Sales by Type (2018-2024) & (K Units)
Table 82. Asia Recombinant Antihemophilic Factor Sales by Type (2024-2029) & (K Units)
Table 83. Asia Recombinant Antihemophilic Factor Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Recombinant Antihemophilic Factor Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Recombinant Antihemophilic Factor Sales by Application (2018-2024) & (K Units)
Table 86. Asia Recombinant Antihemophilic Factor Sales by Application (2024-2029) & (K Units)
Table 87. Asia Recombinant Antihemophilic Factor Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Recombinant Antihemophilic Factor Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Recombinant Antihemophilic Factor Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Recombinant Antihemophilic Factor Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Recombinant Antihemophilic Factor Sales by Region (2018-2024) & (K Units)
Table 93. Asia Recombinant Antihemophilic Factor Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales by Country (2024-2029) & (K Units)
Table 107. Takeda Company Information
Table 108. Takeda Description and Major Businesses
Table 109. Takeda Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 110. Takeda Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Takeda Recent Developments
Table 112. Bayer Company Information
Table 113. Bayer Description and Major Businesses
Table 114. Bayer Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 115. Bayer Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Bayer Recent Developments
Table 117. CSL Company Information
Table 118. CSL Description and Major Businesses
Table 119. CSL Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 120. CSL Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. CSL Recent Developments
Table 122. Pfizer Company Information
Table 123. Pfizer Description and Major Businesses
Table 124. Pfizer Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 125. Pfizer Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Pfizer Recent Developments
Table 127. Biogen Company Information
Table 128. Biogen Description and Major Businesses
Table 129. Biogen Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 130. Biogen Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Biogen Recent Developments
Table 132. Octapharma Company Information
Table 133. Octapharma Description and Major Businesses
Table 134. Octapharma Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 135. Octapharma Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Octapharma Recent Developments
Table 137. Novo Nordisk Company Information
Table 138. Novo Nordisk Description and Major Businesses
Table 139. Novo Nordisk Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 140. Novo Nordisk Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Novo Nordisk Recent Developments
Table 142. Sanofi Company Information
Table 143. Sanofi Description and Major Businesses
Table 144. Sanofi Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 145. Sanofi Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Sanofi Recent Developments
Table 147. Sobi Company Information
Table 148. Sobi Description and Major Businesses
Table 149. Sobi Recombinant Antihemophilic Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 150. Sobi Recombinant Antihemophilic Factor Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Sobi Recent Developments
Table 152. Key Raw Materials Lists
Table 153. Raw Materials Key Suppliers Lists
Table 154. Recombinant Antihemophilic Factor Distributors List
Table 155. Recombinant Antihemophilic Factor Customers List
Table 156. Recombinant Antihemophilic Factor Market Trends
Table 157. Recombinant Antihemophilic Factor Market Drivers
Table 158. Recombinant Antihemophilic Factor Market Challenges
Table 159. Recombinant Antihemophilic Factor Market Restraints
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Antihemophilic Factor Product Picture
Figure 2. Global Recombinant Antihemophilic Factor Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Recombinant Antihemophilic Factor Market Share by Type in 2022 & 2029
Figure 4. 200IU Product Picture
Figure 5. 250IU Product Picture
Figure 6. Global Recombinant Antihemophilic Factor Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Recombinant Antihemophilic Factor Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Recombinant Antihemophilic Factor Report Years Considered
Figure 11. Global Recombinant Antihemophilic Factor Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Recombinant Antihemophilic Factor Revenue 2018-2029 (US$ Million)
Figure 13. Global Recombinant Antihemophilic Factor Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 14. Global Recombinant Antihemophilic Factor Revenue Market Share by Region (2018-2029)
Figure 15. Global Recombinant Antihemophilic Factor Sales 2018-2029 ((K Units)
Figure 16. Global Recombinant Antihemophilic Factor Sales Market Share by Region (2018-2029)
Figure 17. US & Canada Recombinant Antihemophilic Factor Sales YoY (2018-2029) & (K Units)
Figure 18. US & Canada Recombinant Antihemophilic Factor Revenue YoY (2018-2029) & (US$ Million)
Figure 19. Europe Recombinant Antihemophilic Factor Sales YoY (2018-2029) & (K Units)
Figure 20. Europe Recombinant Antihemophilic Factor Revenue YoY (2018-2029) & (US$ Million)
Figure 21. China Recombinant Antihemophilic Factor Sales YoY (2018-2029) & (K Units)
Figure 22. China Recombinant Antihemophilic Factor Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Asia (excluding China) Recombinant Antihemophilic Factor Sales YoY (2018-2029) & (K Units)
Figure 24. Asia (excluding China) Recombinant Antihemophilic Factor Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales YoY (2018-2029) & (K Units)
Figure 26. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue YoY (2018-2029) & (US$ Million)
Figure 27. The Recombinant Antihemophilic Factor Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of Recombinant Antihemophilic Factor in the World: Market Share by Recombinant Antihemophilic Factor Revenue in 2022
Figure 29. Global Recombinant Antihemophilic Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Recombinant Antihemophilic Factor Sales Market Share by Type (2018-2029)
Figure 31. Global Recombinant Antihemophilic Factor Revenue Market Share by Type (2018-2029)
Figure 32. Global Recombinant Antihemophilic Factor Sales Market Share by Application (2018-2029)
Figure 33. Global Recombinant Antihemophilic Factor Revenue Market Share by Application (2018-2029)
Figure 34. US & Canada Recombinant Antihemophilic Factor Sales Market Share by Type (2018-2029)
Figure 35. US & Canada Recombinant Antihemophilic Factor Revenue Market Share by Type (2018-2029)
Figure 36. US & Canada Recombinant Antihemophilic Factor Sales Market Share by Application (2018-2029)
Figure 37. US & Canada Recombinant Antihemophilic Factor Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada Recombinant Antihemophilic Factor Revenue Share by Country (2018-2029)
Figure 39. US & Canada Recombinant Antihemophilic Factor Sales Share by Country (2018-2029)
Figure 40. U.S. Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 41. Canada Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 42. Mexico Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 43. Europe Recombinant Antihemophilic Factor Sales Market Share by Type (2018-2029)
Figure 44. Europe Recombinant Antihemophilic Factor Revenue Market Share by Type (2018-2029)
Figure 45. Europe Recombinant Antihemophilic Factor Sales Market Share by Application (2018-2029)
Figure 46. Europe Recombinant Antihemophilic Factor Revenue Market Share by Application (2018-2029)
Figure 47. Europe Recombinant Antihemophilic Factor Revenue Share by Country (2018-2029)
Figure 48. Europe Recombinant Antihemophilic Factor Sales Share by Country (2018-2029)
Figure 49. Germany Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 50. France Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 51. UK Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 52. Italy Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 53. Russia Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 54. China Recombinant Antihemophilic Factor Sales Market Share by Type (2018-2029)
Figure 55. China Recombinant Antihemophilic Factor Revenue Market Share by Type (2018-2029)
Figure 56. China Recombinant Antihemophilic Factor Sales Market Share by Application (2018-2029)
Figure 57. China Recombinant Antihemophilic Factor Revenue Market Share by Application (2018-2029)
Figure 58. Asia Recombinant Antihemophilic Factor Sales Market Share by Type (2018-2029)
Figure 59. Asia Recombinant Antihemophilic Factor Revenue Market Share by Type (2018-2029)
Figure 60. Asia Recombinant Antihemophilic Factor Sales Market Share by Application (2018-2029)
Figure 61. Asia Recombinant Antihemophilic Factor Revenue Market Share by Application (2018-2029)
Figure 62. Asia Recombinant Antihemophilic Factor Revenue Share by Region (2018-2029)
Figure 63. Asia Recombinant Antihemophilic Factor Sales Share by Region (2018-2029)
Figure 64. Japan Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 65. South Korea Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 66. China Taiwan Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 67. Southeast Asia Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 68. India Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 69. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Revenue Share by Country (2018-2029)
Figure 74. Middle East, Africa and Latin America Recombinant Antihemophilic Factor Sales Share by Country (2018-2029)
Figure 75. Brazil Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 76. Mexico Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 77. Turkey Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 78. Israel Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 79. GCC Countries Recombinant Antihemophilic Factor Revenue (2018-2029) & (US$ Million)
Figure 80. Recombinant Antihemophilic Factor Value Chain
Figure 81. Recombinant Antihemophilic Factor Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed